Q2 revenue reached $33.7M, with core product sales down 19% year-over-year amid competitive and market headwinds. The Alcon collaboration brought $6.5M in Q2 and is expected to contribute $30–$40M in 2026. Full-year guidance was withdrawn pending a strategic business assessment.Based on RxSight, In…
Q2 revenue reached $33.7M, with core product sales down 19% year-over-year amid competitive pressures. The Alcon collaboration brought $6.5M in milestone revenue and will contribute $30M–$40M in 2026. Full-year guidance was withdrawn pending a business reassessment.Based on RxSight, Inc. [RXST] Q2…
Q2 2026 revenue was $33.7 million, with product sales down 19% year-over-year amid competitive pressures. Net loss widened slightly, while a strategic Alcon collaboration contributed $6.5 million and supports long-term growth. Guidance for 2026 was withdrawn pending a business review.Original docum…
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. NASDAQ:RXST today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight’s common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138…
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. NASDAQ:RXST today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Offi…
A new collaboration with Alcon will drive development of adjustable presbyopia-correcting IOLs, expanding market reach and validating the technology. Q2 revenue declined due to competitive trialing, prompting a revised 2026 outlook, but gross margin guidance was raised. Commercial and R&D investmen…
Q2 2026 revenue is expected at $32–34 million, with full-year guidance revised to $140–160 million and gross margin raised to 73–75%. The product pipeline advances with next-gen adjustable lenses and a strategic collaboration, despite commercial headwinds.Original document: RxSight, Inc. [RXST] Pre…
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageFor questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected].
RxSight Sees 2Q Rev $32M-$34M >RXST
RxSight Sees 2026 Rev $140M-$160M >RXST
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE:ALC, the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. NASDAQ:RXST, an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cata…
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.Shareholders should contact the firm immed…
